Clinical Trials · NCT03552757
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,210
- Start date
- Jun 2018
- Locations
- 147 sites, 13 countries
- Primary endpoint
- Change in Body Weight (%) - Semaglutide 2.4 mg Versus Placebo